Opinion

Video

The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma

Author(s):

Guru P. Sonpavde, MD

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Vikram M. Narayan, MD
Sumanta Kumar Pal, MD, FASCO,
Kohei Shitara, MD
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Kian-Huat Lim, MD, PhD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Kelly N. Fitzgerald, MD
May 29th 2024

Nivolumab/Cabozantinib Combination Displays Activity in Non-Clear Cell RCC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Vikram M. Narayan, MD, of Emory University Hospital
May 23rd 2024

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Allliance; associate professor, Department of Medicine, Division of Oncology, clinical director, Genitourinary Cancers Program, University of Washington School of Medicine; associate member, Clinical Research Division, Fred Hutchinson Cancer Center
May 23rd 2024

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer